Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 4/2015

01-10-2015 | Review Article

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Authors: Masao Omata, Tatsuo Kanda, Osamu Yokosuka, Darrell Crawford, Mamun Al-Mahtab, Lai Wei, Alaaeldin Ibrahim, George K. K. Lau, Barjesh C. Sharma, Saeed S. Hamid, Wan-Long Chuang, A. Kadir Dokmeci

Published in: Hepatology International | Issue 4/2015

Login to get access

Abstract

Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4–1.0, 14.7, 0.1–0.3, 0.9–1.9, 1.0–2.0, 5, 4.4–8.6 and 0.5–1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60–70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.
Appendix
Available only for authorised users
Literature
1.
2.
Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1990;87:6547–6549PubMedCentralPubMedCrossRef
3.
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61–80PubMedCrossRef
4.
5.
Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–561PubMedCrossRef
6.
Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73–81PubMedCrossRef
7.
Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012;56:78–84PubMedCrossRef
8.
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762–768PubMedCrossRef
9.
Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. J Hepatol 2015 Jan 2 (in press)
10.
Dore GJ, Law G, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171–184PubMedCrossRef
11.
Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection; genotyping and its clinical role. Future Microbiol 2006;1:103–112PubMedCrossRef
12.
Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, et al. Distribution of interferon lamda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: analysis from the PREDICT and CHARIOT studies. J Gastroenterol Hepatol 2014;29:179–184PubMedCrossRef
13.
Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinghe D, Liddle C, et al. Effectiveness of intereferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 2003;178:267–271PubMed
14.
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high dose peginterferon alpha-2A on virological response rates in hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2009;50:1045–1055PubMedCrossRef
15.
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–2410PubMedCrossRef
16.
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Bocepravir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–206PubMedCentralPubMedCrossRef
17.
Khan M, Husain M, Yano M, Hashizume K, Yousuf M, Tanaka E, et al. Comparison of seroepidemiology of hepatitis C in blood donors between Bangladesh and Japan. Gastroenterol Jpn. 1993;28:28–31PubMedCrossRef
18.
Akbar SMF, Hossain M, Hossain MF, Sarker S, Hossain SAS, Tanimoto K, et al. Seroepidemiology of hepatitis viruses of chronic liver diseases in Bangladesh: high prevalence of HCV among blood donors and healthy persons. Hepatol Res. 1997;7:113–120CrossRef
19.
Mahtab MA, Karim F, Foster G, Akbar SMF, Rahman S. Prevalence and risk factors of asymptomatic HCV infection in Bangladesh. J Clin Exp Hepatol 2011;1:13–16CrossRef
20.
Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010;10:208PubMedCentralPubMedCrossRef
21.
Rudra S, Chakrabarty P, Poddar B. Prevalence of hepatitis B and hepatitis C virus infection in human of Mymensingh, Bangladesh. Mymensingh Med J 2011;20:183–186PubMed
22.
Rudra S, Chakrabarty P, Hossain MA, Akhter H, Bhuiyan MR. Seroprevalence of Hepatitis B, Hepatitis C, HIV Infections in blood donors of Khulna, Bangladesh. Mymensingh Med J 2010;19:515–519PubMed
23.
Aliberch MRM, Buxó AE, Gil BM, Rodriguez CC, de FrutosGallego E, Molina CG, et al. Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants. Gac Sanit 2010;24:288–292CrossRef
24.
Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010;17:327–335PubMedCrossRef
25.
Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000;18:145–150PubMed
26.
Chakrabarty P, Rudra S, Hossain MA. Prevalence of HBV and HCV among the multi-transfused beta thalassemic major patients in a Day Care Centre of Blood Transfusion Department of Mymensingh Medical College Hospital. Mymensingh Med J 2014;23:235–241PubMed
27.
Waheed Y, Shafi T, Safi SZ, Qadri I. HCV in Pakistani: a systematic review of prevalence genotypes and risk factors. World J Gastroenterol 2009;15:5647–5653PubMedCentralPubMedCrossRef
28.
29.
Mahtab MA, Rahman S, Khan M, Karim F, Sharif NM, Shrestha A. Genotypes of HCV in Bangladesh: experience from a tertiary cenrtre. Hungarian Med J 2008;2:577–581CrossRef
30.
Mahtab MA, Rahman S, Karim MF, Khan M. Genotypes of HCV in Bangladesh: experience from a tertiary centre. J Gastroenterol Hepatol 2008;23(Suppl):27–28
31.
Islam ASM. Thesis submitted to Bangabandhu Sheiikh Mujib Medical University for fulfillment of Doctor of Medicine in Hepatology 2014
32.
Rahman MZ, Perveen S, Mahmuduzzaman M, Rahman MA, Chowdhury MS, Huda MN, et al. Peginterferon α-2a and Rivabirin in the Treatment of Chronic Hepatitis C. Mymensingh Med J 2014;23:335–340PubMed
33.
Rahman MZ, Ahmed DS, Masud H, Parveen S, Rahman MA, Chowdhury MS, et al. Sustained virological response after treatment in patients with chronic hepatitis C infection—a five year follow up. Bangladesh Med Res Counc Bull 2013;39:11–13PubMedCrossRef
34.
35.
Dai ZC, Qi GM. The Seroprevalence Survey of Virus Hepatitis in China, 1992–1995. Beijing: Scientific and Technical Literature Publishers; 1995: 60–71
36.
Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol (in Chinese) 2011;32(9):888–891
37.
38.
Lu WP, Lin GX, Shi S, Dong JH. Simultaneously high prevalences of hepatitis B and C virus infections in a population in Putian County, China. J Clin Microbiol 2012;50(6):2142–2144PubMedCentralPubMedCrossRef
39.
Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2014;29(3):545–553PubMedCentralPubMedCrossRef
40.
Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22(6):832–836PubMedCrossRef
41.
Zhao SH, Chu YL, Cheng DX, Waqar AB, Yu Q, Yang PH, et al. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. Int J Clin Pract 2009;63(9):1334–1339PubMedCrossRef
42.
Li QR, Zhang CJ, Xiong YL, Zhu Y, Tan ZX, Hu YJ, et al. Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin. Zhonghua Gan Zang Bing Za Zhi (in Chinese) 2012;20(5):353–356
43.
Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011;18(8):595–600PubMedCrossRef
44.
45.
46.
Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012;19:560–567PubMedCrossRef
47.
Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar TS, Galal G, et al. Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clin Virol 2013;57:24–28PubMedCrossRef
48.
49.
Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 2003;20:381–387PubMedCrossRef
50.
Abdelwahab S, Rewisha E, Hashem M, Sobhy M, Galal I, Allam WR, et al. Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. Trans R Soc Trop Med Hyg 2012;106:98–103PubMedCrossRef
51.
Galal IF, Zakaria Z, Allam W, Mahmoud MA, Ezzat AR, Osman A, et al. Cross reactive cellular immune response to HCV Genotype 1 and 4 Antigens among Genotype 4 exposed subjects. PLoS One 2014;9:e101264PubMedCentralPubMedCrossRef
52.
Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011;54:1250–1262PubMedCrossRef
53.
El Khayat HR, Fouad YM, El Amin H, Rizk A. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroenterol 2012;33:111–112CrossRef
54.
Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. How to optimize HCV therapy in genotype 4 patients. Liver Int 2013;33 Suppl:141–145
55.
56.
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;Suppl 1:34–59CrossRef
57.
Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013;13:288PubMedCentralPubMedCrossRef
58.
El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989–2013); Do they differ in Egypt? Liver Int 2014 Jun 12;. doi:10.​1111/​liv.​12617 PubMed
59.
Recker C, Islam KM. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis 2014
60.
61.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–1887PubMedCrossRef
62.
Ruane PJ, Ain D, Meshrekey R, Riad J, Soliman M, Mikhail S, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. J Hepatol 2014;60(suppl 1):S503–S504CrossRef
63.
Hezode C, Marcellin P, Pol S, Hassanein T, Fleischer-Stepniewska K, Baykal T, et al. Results from the phase 2 PEARL-I Study: interferon-free regimens of ABT-450/R+ ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. J Hepatol 2014;60(suppl 1):S24CrossRef
64.
Hassanein T, Sims K, Bennett M, Gitlin N, Lawitz E, Nguyen T, et al. All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naïve patients with chronic HCV genotype 4 infection. J Hepatol 2014;60(suppl 1):S472CrossRef
65.
66.
Wong HK, Lee CK, Leung JN, Tsoi WC, Lin CK. Risk factor analysis of hepatitis C virus infection among Chinese blood donors in Hong Kong. Transfus Med 2012;22(2):133–136PubMedCrossRef
67.
68.
Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol 2014;29(1):116–120PubMedCrossRef
69.
Seto WK, Lai CL, Fung J, Hung I, Yuen J, Young J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010;53(3):444–448PubMedCrossRef
70.
Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008;198(6):808–812PubMedCrossRef
71.
72.
Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Aggarwal R, et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. J Clin Exp Hepatol 2014;4:106–116PubMedCentralPubMedCrossRef
73.
Gupta N, Kumar V, Kaur A. Seroprevalence of HIV, HBV, HCV and syphilis in voluntary blood donors. Indian J Med Sci 2004;58:255–257PubMed
74.
Jain A, Kar P, Madan K, Das UP, Budhiraja S, Gopalkrishna V, et al. Hepatitis C virus infection in sporadic fulminant viral hepatitis in North India: cause or cofactor? Eur J Gastroenterol Hepatol. 1999;11:1231–1237PubMedCrossRef
75.
Das BR, Kundu B, Khandapkar R, Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002;45:323–328PubMed
76.
Mukhopadhya A. Hepatitis C in India. J Biosci 2008;33(465):473
77.
Kapoor D, Saxena R, Sood B, Sarin SK. Blood transfusion practices in India: results of a national survey. Indian J Gastroenteral 2000;19:64–67
78.
Bhattacharya DK, Bhattacharjee S, De M, Lahiri P. Prevalence ofhepatitis C in transfusion dependent thalassaemics & haemophilics. Indian J Med Res. 1991;94:430–432PubMed
79.
Amarapurkar DN, Kumar A, Vaidya S, et al. Frequency of hepatitis B, C and D and human immunodeficiency virus infections in multitransfused thalassemics. Indian J Gastroenterol. 1992;11:80–81PubMed
80.
Williams TN, Wonke B, Donohue SM. A study of hepatitis B and C prevalence and liver function in multiply transfused thalassemic and their parents. Indian Pediatr. 1992;29:1119–1124PubMed
81.
Agarwal MB, Malkan GH, Bhave AA, Vishwanathan C, Billa V, Dube SR, et al. Antibody to hepatitis-C virus in multi-transfused thalassaemics-Indian experience. J Assoc Physicians India. 1993;41:195–197PubMed
82.
Choudhry VP, Acharya SK. Hepatitis B, C & D viral markers in multitransfuse thalassemic children: long-term complications and present management. Indian J Pediatr. 1995;62:655–668PubMedCrossRef
83.
Saha MK, Chakrabarti S, Panda S, Naik TN, Manna B, Chatterjee A, et al. Prevalence of HCV & HBV infection amongst HIV seropositive intravenous drug users & their non-injecting wives in Manipur, India. Indian J Med Res 2000;111:37–39PubMed
84.
Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injection drug users at a national andlocal level in developing and translational countries, and gender and age distribution. Sex Transm Infect 2006;82(suppl 3):10–17
85.
Sarkar K, Mitra S, Bal B, Chakrabarti S, Bhattacharya SK. Rapidspread of hepatitis C and needle exchange programme in Kolkata, India. Lancet 2003;361:1301–1302PubMedCrossRef
86.
Ganju SA, Goel A. Prevalence of HBV and HCV infection amonghealth care workers (HCWs). J Commun Dis 2000;32:228–230PubMed
87.
Kalaskar A, Kumar M. Prevalence of Hepatitis B and Hepatitis C viruses among nurses and nursing students in a medical collegehospital in southern Tamil Nadu, India. Int Res J Microbiol 2012;3:10–13
88.
Duseja A, Arora L, Masih B, Singh H, Gupta A, Behera D, et al. Hepatitis B and C virus prevalence and prevention in health care workers. Trop Gastoenterol 2002;23(3):125–126
89.
Jindal N, Jindal M, Jilani N, Kar P. Seroprevalence of hepatis C virus (HCV) in health care workers of tertiary care centre in New Delhi. Indian J Med Res 2006;123:179–180PubMed
90.
91.
Parthiban R, Shanmugam S, Velu V, Nandakumar S, Dhevahi E, Thangaraj K, et al. Transmission of hepatitisC virus from asymptomatic mother to child in southern India. Int J Infect Dis 2009;13:e394–e400PubMedCrossRef
92.
Barua P, Mahanta J, Medhi GK, Dale J, Paranjape RS, Thongamba G. Sexual activity as a risk factor for hepatitis C virus (HCV) transmission among female sex workers in Nagaland. Indian J Med Res 2012;136(suppl l):30–35
93.
Marx MA, Murugavel KG, Tarwater PM, SriKrishnan AK, Thomas DL, Solomon S, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis 2003;37:514–520PubMedCrossRef
94.
Solomon SS, Srikrishnan AK, Sifakis F, Mehta SH, Vasudevan CK, Balakrishnan P, et al. The emerging HIVepidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav 2010;14:1001–1010PubMedCrossRef
95.
Pereira M, Tripathy S, Inamdar V, Ramesh K, Bhavsar M, Date A, et al. Lack of evidence for sexualtransmission of hepatitis C virus in patients attending STD clinics in Pune, India. Sex Transm Infect 2003;79:424–429CrossRef
96.
Reddy AK, Murthy KV, Lakshmi V. Prevalence of HCV infection in patients on haemodialysis: survey by antibody and core antigen detection. Indian J Med Microbiol 2005;23:106–110PubMedCrossRef
97.
Jaiswal SK, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalenceof hepatitis viruses among chronic renal failure patients on haemodialysisin Central India. Dial Transplant 2002;31:234–240
98.
Mittal G, Gupta P, Thakuria B, Mukhiya GK, Mitta M. Profile of hepatitisB virus, hepatitis C virus, hepatitis d virus and human immunodeficiencyvirus infections in hemodialysis patients of a tertiarycare hospital in Uttarakhand. J Clin Exp Hepatol 2013;3:24–28PubMedCentralPubMedCrossRef
99.
John GT. Infections after renal transplantation in India. Transplant Rev. 1999;13:183–191CrossRef
100.
Chandra M, Khaja MN, Hussain MM, Poduri CD, Farees N, Habeeb MA, et al. Prevalence of hepatitisB and hepatitis C viral infections in Indian patients with chronicrenal failure. Intervirology 2004;47:374–376PubMedCrossRef
101.
Agarwal SK, Dash SC, Irshad M. Hepatitis C virus infection duringhaemodialysis in India. J Assoc Physicians India. 1999;47:1139–1143PubMed
102.
Reddy AK, Murthy KV, Lakshmi V. Prevalence of HCV infection inpatients on haemodialysis: survey by antibody and core antigendetection. Indian J Med Microbiol 2005;23:106–110PubMedCrossRef
103.
Narahari S, Juwle A, Basak S, Saranath D. Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort. Infect Genet Evol 2009;9(4):643–645PubMedCrossRef
104.
Amarapurkar D, Dhorda M, Kirpalani A, Amarapurkar A, Kankonkar S. Prevalence of hepatitis C genotypes in Indian patients and their clinical significance. J Assoc Physicians India 2001;49:983–985PubMed
105.
Abraham R, Ramakrishna B, Balekuduru A, Daniel HD, Abraham P, Eapen CE, et al. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease. Indian J Gastroenterol 2009;28:53–58PubMedCrossRef
106.
Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006;78:452–458PubMedCrossRef
107.
Raghuraman S, Shaji RV, Sridharan G, Radhakrishnan S, Chandy G, Ramakrishna BS, et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. J Clin Virol 2003;26:61–69PubMedCrossRef
108.
Narhari S, Juwle A, Basak S, Saranath D. Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort. Infect Genet Evol 2009;9:643–645CrossRef
109.
Das BR, Kundu B, Khanapkar R, Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002;45:323–328PubMed
110.
Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004;119:145–148PubMed
111.
Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes & its association with viral load. Indian J Med Res 2011;133:326–331PubMedCentralPubMed
112.
Gupta AC, Trehanpati N, Sukriti S, Hissar S, Midha V, Sood A, et al. Interleukin28b CC genotype predicts early treatment response and CT/TT genotypes predicts non response in patients infected with HCV genotype 3. J Med Virol 2014;86(4):707–712PubMedCrossRef
113.
Sood A, Midha V, Goyal O, Hissar S, Sharma SK, Khanna P. Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve ‘real-life’ patients in India. Indian J Gastroenterol 2014;33:343–349PubMedCrossRef
114.
CTRI/2014/02/004403A Phase 3b, Multi-center, randomized, open-label, study to evaluate the safety and efficacy of sofosbuvir plus ribavirin in treatment-naïve adults with chronic genotype 1 or 3 hepatisis C virus infection
115.
116.
Tanaka H, Hiyama T, Tsukuma H, Okubo Y, Yamano H, Kitada A, et al. Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan. Cancer Causes Control. 1994;5:409–413PubMedCrossRef
117.
Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011;54:185–195PubMedCrossRef
118.
Kanda T, Yokosuka O, Imazeki F, Saisho H, Nagao K. Hepatitis C infection with history of tuberculosis in Japan: no association with progression of liver fibrosis. J Gastroenterol Hepatol 2004;19:717–719PubMedCrossRef
119.
Takano S, Omata M, Ohto M, Satomura Y. Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases. Dig Dis Sci. 1994;39:28–32PubMedCrossRef
120.
Takano S, Nakamura K, Kawai S, Yokosuka O, Satomura Y, Omata M. Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology. 1996;23:708–712PubMedCrossRef
121.
Iwamura K. Clinicopathological aspects of liver diseases associated with early history of tattooing. Tokai J Exp Clin Med. 1988;13:191–218PubMed
122.
Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, et al. Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use. Hepatol Res 2013;43:1013–1019PubMed
123.
Kogure T, Ueno Y, Kanno N, Fukushima K, Yamagiwa Y, Nagasaki F, et al. Sustained viral response of a case of acute hepatitis C virus infection via needle-stick injury. World J Gastroenterol 2006;12:4757–4760PubMedCentralPubMed
124.
Murakami J, Nagata I, Iitsuka T, Okamoto M, Kaji S, Hoshika T, et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol Res 2012;42:648–657PubMedCrossRef
125.
Nakayama H, Sugai Y, Ikeya S, Inoue J, Nishizawa T, Okamoto H. Molecular investigation of interspousal transmission of hepatitis C virus in two Japanese patients who acquired acute hepatitis C after 40 or 42 years of marriage. J Med Virol 2005;75:258–266PubMedCrossRef
126.
Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One 2013;8:e73615PubMedCentralPubMedCrossRef
127.
Fukuda Y, Nakano I, Katano Y, Toyoda H, Imoto M, Takamatsu J, et al. Assessment and treatment of liver disease in Japanese haemophilia patients. Haemophilia. 1998;4:595–600PubMedCrossRef
128.
Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 2014;5:1–5
129.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401PubMedCrossRef
130.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–1104PubMedCrossRef
131.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–1109PubMedCrossRef
132.
Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, et al. IL-28B predicts response to chronic hepatitis C therapy—fine-mapping and replication study in Asian populations. J Gen Virol 2011;92:1071–1081PubMedCrossRef
133.
Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci. 1994;39:977–982PubMedCrossRef
134.
Yokosuka O, Iwama S, Suzuki N, Takashi M, Hirai Y, Uchiumi K, et al. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study. Intervirology 2004;47:328–334PubMedCrossRef
135.
Fujiwara K, Yokosuka O, Komine F, Moriyama M, Kato N, Yoshida H, et al. Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Liver Int 2006;26:520–528PubMedCrossRef
136.
Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007;22:645–652PubMed
137.
Kanda T, Imazeki F, Azemoto R, Yonemitsu Y, Mikami S, Kita K, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011;56:3335–3342PubMedCrossRef
138.
Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012;19:e134–e142PubMedCentralPubMedCrossRef
139.
Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014;49:138–147PubMedCentralPubMedCrossRef
140.
Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014;49:941–953PubMedCrossRef
141.
Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol 2013;59:11–17PubMedCrossRef
142.
Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol 2014;12:1029–1037PubMedCrossRef
143.
Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, et al. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int 2014;34:78–88PubMedCrossRef
144.
145.
Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141(881–889):e1PubMed
146.
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083–2091PubMedCentralPubMedCrossRef
147.
Mizokami M, Takehara T, Yokosuka O, Sakamoto N, Korenaga M, Mochizuki H, et al. 100% SVR4 in Japanese patients with chronic genotype 1 hepatitis C virus infection receiving ledipasvir/sofosbuvir fixed dose combination for 12 weeks: results from a Multicenter Phase 3 Study. Hepatology 2014;60 Suppl S1:1130A
148.
149.
Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J 2010;16:S15–S23PubMed
150.
Janjua NZ, Hamza HB, Islam M, Tirmizi SF, Siddiqui A, Jafri W, et al. Health care risk factors among women and personal behaviors among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. J Viral Hepat 2010;17(5):317–326PubMedCrossRef
151.
Ahmed B, Ali T, Qureshi H, Hamid S. Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. Hepatol Int 2013;7:500–507PubMedCrossRef
152.
Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S. Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Infect Dis 2002;6:272–275PubMedCrossRef
153.
Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol 2009;81:1189–1197PubMedCrossRef
154.
Mumtaz K, Hamid SS, Moatter T, Abid S, Shah HA, Jafri W. Distribution of hepatitis C virus genotypes and its response to treatment in Pakistani patients. Saudi Med J 2008;29:1671–1673PubMed
155.
Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148–155PubMedCrossRef
156.
Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006;49:99–106PubMedCrossRef
157.
Yang JF, Lin CI, Huang JF, Dai CY, Lin WY, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010;26:461–469PubMedCrossRef
158.
Lee PL, Wang JH, Tung HD, Lee CM, Lu SN. A higher than expected recovery rate from hepatitis C infection amongst adolescents: a community study in a hepatitis C-endemic township in Taiwan. Trans R Soc Trop Med Hyg 2004;98:367–372PubMedCrossRef
159.
Huang CF, Huang JF, Dai CY, Yu ML, Lu SN, Hsieh MY, et al. Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. Trans R Soc Trop Med Hyg 2008;102:929–934PubMedCrossRef
160.
Huang JF, Lu SN, Chue PY, Lee CM, Yu ML, Chuang WL, et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. Epidemiol Infect 2001;127:485–492PubMedCentralPubMed
161.
Yu ML, Chuang WL, Wang LY, Dai CY, Chiou SS, Sung MH, et al. Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. J Gastroenterol Hepatol 2000;15:1404–1410PubMedCrossRef
162.
Chiou SS, Huang JF, Chang TT, Hsieh MY, Dai CY, Yu ML, et al. SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan. Digestion 2006;74:208–214PubMed
163.
Chang JM, Huang CF, Chen SC, Dai CY, Yeh ML, Huang JF, et al. Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients. Int J Med Sci 2014;11:436–441PubMedCentralPubMedCrossRef
164.
Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, et al. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol 2014;60:253–259PubMedCrossRef
165.
Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF, et al. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PLoS One 2014;9:e94791PubMedCentralPubMedCrossRef
166.
Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336–345PubMedCrossRef
167.
Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, et al. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001;65:58–65PubMedCrossRef
168.
Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML. Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011;53:367–368PubMedCrossRef
169.
Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012;56:34–40PubMedCrossRef
170.
Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011;53:7–13PubMedCrossRef
171.
Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res. 1995;15:611–616PubMedCrossRef
172.
Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996;111:1307–1312PubMedCrossRef
173.
Yu ML, Dai CY, Chen SC, Lee LP, Hsieh MY, Lin ZY, et al. High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infect Dis 2005;5:27PubMedCentralPubMedCrossRef
174.
Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553–559PubMedCentralPubMedCrossRef
175.
Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884–1893PubMedCrossRef
176.
Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260–1269PubMedCrossRef
177.
Yu ML, Dai CY, Chen SC, Lee LP, Huang JF, Lin ZY, et al. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res 2004;63:25–32PubMedCrossRef
178.
Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884–1893PubMedCrossRef
179.
Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12:283–291PubMedCrossRef
180.
Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005;20:727–732PubMedCrossRef
181.
Yu ML, Dai CY, Lee LP, Hou NJ, Hsieh MY, Huang JF, et al. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int 2006;26:1187–1195PubMedCrossRef
182.
Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, et al. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. J Gastroenterol Hepatol 2013;28:1515–1520PubMedCrossRef
183.
Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, et al. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS One 2013;8:e58882PubMedCentralPubMedCrossRef
184.
185.
186.
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597–1605PubMedCrossRef
187.
188.
189.
190.
191.
192.
193.
194.
Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int J Infect Dis 2009;13:274–284PubMedCrossRef
195.
Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006;21:299–305PubMedCrossRef
196.
Karaca C, Cakaloğlu Y, Demir K, Ozdil S, Kaymakoğlu S, Badur S, et al. Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci 2006;51:365–369PubMedCrossRef
197.
Bozdayi AM, Aslan N, Bozdayi G, Türkyilmaz AR, Sengezer T, Wend U, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004;149:2115–2129PubMedCrossRef
198.
Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008;12:239–244PubMedCrossRef
199.
Simsek H, Alp A, Yilmaz B, Balaban YH, Altun B, Uzun O, et al. The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C. Eur J Gastroenterol Hepatol 2012;24:1113–1115PubMedCrossRef
200.
Senturk H, Uzunalimoglu O, Batur Y, Simsek I, Mert A, Ozbay G, et al. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci. 1997;42:1438–1444PubMedCrossRef
201.
Simsek H, Tatar G, Savas C, Telatar H. Treatment of chronic hepatitis C infection with interferon alpha-2a in a Turkish population. J Int Med Res. 1996;24:132–137PubMed
202.
Süoğlu DOD, Elkabes B, Sökücü S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children withhepatitis C? J Pediatr Gastroenterol Nutr 2002;34:199–206CrossRef
203.
Senturk H, Ersoz G, Ozaras R, Kaymakoglu S, Bozkaya H, Akdogan M, et al. Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial. Dig Dis Sci 2003;48(6):1124–1129PubMedCrossRef
204.
Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 2008;36:341–344PubMedCrossRef
205.
Coban S, Idilman R, Erden E, Tüzün A. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology 2011;58:1301–1306PubMedCrossRef
206.
Yenice N, Mehtap O, Gümrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006;17:94–98PubMed
207.
Kim do Y, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586–594PubMedCrossRef
208.
Jazag A, Puntsagdulam N, Chinburen J. Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia. Korean J Intern Med 2012;27:121–127PubMedCentralPubMedCrossRef
209.
Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health 2011;42:609–615PubMed
210.
Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic) 2012;11:311–320CrossRef
211.
Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J Res Med Sci 2013;18:674–682PubMedCentralPubMed
212.
Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409–435PubMedCrossRef
Metadata
Title
Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries
Authors
Masao Omata
Tatsuo Kanda
Osamu Yokosuka
Darrell Crawford
Mamun Al-Mahtab
Lai Wei
Alaaeldin Ibrahim
George K. K. Lau
Barjesh C. Sharma
Saeed S. Hamid
Wan-Long Chuang
A. Kadir Dokmeci
Publication date
01-10-2015
Publisher
Springer India
Published in
Hepatology International / Issue 4/2015
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-015-9630-4

Other articles of this Issue 4/2015

Hepatology International 4/2015 Go to the issue

Editorial

Minimalist approach to donor hepatectomy

Review Article

Liver transplantation in acute on chronic liver failure: challenges and an algorithm for patient selection and management

Original Article

Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C

Original Article

Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis

Original Article

The role of interstitial Cajal-like cells in the formation of cholesterol stones in guinea pig gallbladder

Review Article

Hepatic encephalopathy in acute-on-chronic liver failure
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits